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RESEARCH ARTICLE

Open Access

Fetal ERAP2 variation is associated with
preeclampsia in African Americans in a casecontrol study
Lori D Hill1, DaShaunda D Hilliard1, Timothy P York2, Sindhu Srinivas3, Juan P Kusanovic4,6, Ricardo Gomez5,6,
Michal A Elovitz3, Roberto Romero4 and Jerome F Strauss III1*

Abstract
Background: Preeclampsia affects 3-8% of pregnancies and is a major cause of maternal and perinatal morbidity
and mortality worldwide. This complex disorder is characterized by alterations in the immune and vascular systems
and involves multiple organs. There is strong evidence for a genetic contribution to preeclampsia. Two different
single nucleotide polymorphisms (SNPs) in the endoplasmic reticulum aminopeptidase 2 (ERAP2) gene were recently
reported to be associated with increased risk for preeclampsia in two different populations. ERAP2 is expressed in
placental tissue and it is involved in immune responses, inflammation, and blood pressure regulation; making it is
an attractive preeclampsia candidate gene. Furthermore, ERAP2 expression is altered in first trimester placentas of
women destined to develop preeclampsia.
Methods: A case-control design was used to test for associations between two SNPs in ERAP2, rs2549782 and
rs17408150, and preeclampsia status in 1103 Chilean maternal-fetal dyads and 1637 unpaired African American
samples (836 maternal, 837 fetal).
Results: We found that the fetal minor allele (G) of rs2549782 was associated with an increased risk for
preeclampsia in the African American population (P = 0.009), but not in the Chilean population. We found no
association between rs17408150 and risk for preeclampsia in the Chilean population. Association between
rs17408150 and risk for preeclampsia was not tested in the African American population due to the absence of the
minor allele in this population.
Conclusions: We report an association between fetal ERAP2 and preeclampsia in an African American population.
In conjunction with previous studies, which have found maternal associations with this gene in an Australian/New
Zealand population and a Norwegian population, ERAP2 has now been associated with preeclampsia in three
populations. This provides strong evidence that ERAP2 plays a role in the development of preeclampsia.

Background
Preeclampsia (PE) affects 3-8% of pregnancies worldwide, with rates varying by ethnicity, and leads to potentially devastating complications for both the mother and
fetus[1,2]. Preeclampsia is clinically characterized by
high blood pressure and proteinuria, usually occurring
after 20 weeks of gestation. Although this serious disorder is common during pregnancy, its etiology remains
* Correspondence: jfstrauss@vcu.edu
1
Department of Obstetrics and Gynecology and Center on Health Disparities,
Virginia Commonwealth University School of Medicine, Richmond, VA,
23298, United States
Full list of author information is available at the end of the article

poorly understood[1]. Preeclampsia is considered a disease of the placenta, with shallow trophoblast invasion
[3-5] and poor spiral artery remodeling[6-8] being central features of this disorder. It is postulated that
immune, vascular, and inflammatory disturbances participate in the placental dysfunction that ultimately produces the preeclampsia phenotype[9].
A genetic susceptibility to preeclampsia has been
established with both maternal and fetal genes contributing to disease[2,10-17]. Preeclampsia is a multi-factorial trait, with multiple genes, as well as
environmental and social factors contributing to disease
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risk[18-20]. Johnson et al. recently reported that Endoplasmic reticulum aminopepetidase 2 (ERAP2) was associated with preeclampsia in an Australian/New Zealand
family-based study and a Norwegian case-control study
of maternal samples[21]. Although ERAP2 was associated with risk for preeclampsia in both populations,
different polymorphisms of the gene were identified in
each group. ERAP2 is expressed in the syncytiotrophoblast and it is a member of the oxytocinase subfamily of
M1 aminopeptidases, which are known to play a critical
role in the maintenance of normal pregnancy[22-24].
Additionally, ERAP2 is involved in the regulation of
blood pressure, immune responses, and pro-inflammatory cytokine production[22,25-28]. It was recently
shown that ERAP2 expression was altered in first trimester placentas of pregnancies destined to develop preeclampsia[29]. The involvement of ERAP2 in multiple
pathways known to influence the risk for preeclampsia,
its expression in placental tissue, and the previously
described altered expression of ERAP2 in placentas
before maternal symptoms developed[29]; suggest that
the fetal ERAP2 gene contributes to the development of
preeclampsia.
In the present study, we investigated whether the previously described associations between ERAP2 and risk
for preeclampsia [21] replicated in other ethnic groups
and extended our study design past maternal only samples to also include fetal samples. We examined the
association between ERAP2 and risk for preeclampsia in
two distinct case-control cohorts: Chilean (1103 maternal-fetal dyads) and African American (836 maternal
and 837 fetal samples). We genotyped the two SNPs in
ERAP2, rs17408150 and rs2549782, that were previously
identified as being associated with preeclampsia. Our
results demonstrate that the rs2549782 SNP of the fetal
ERAP2 gene is significantly associated with risk for preeclampsia in the African American population; further
suggesting that this gene plays a key role in the development of disease and may provide insight into the disparity between preeclampsia rates between ethnic groups.

Methods
Chilean study design and population

A case-control study was initiated by searching the clinical database and bank of biological samples of the Perinatology Research Branch (Eunice Kennedy Shriver
National Institute of Child Health and Human Development, NIH, DHHS) and included Hispanic women and
their neonates in the following groups: 1) Cases women with preeclampsia and their neonates (n = 528
dyads); and 2) Controls - women who delivered at term
with a normal pregnancy outcome and their neonates (n
= 575 dyads). Participants received obstetrical care at
the Sótero del Río Hospital in Santiago, Chile (an
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affiliate of the Pontificia Católica de Chile in Santiago,
Chile). Exclusion criteria included: (1) known major
fetal anomaly or demise; (2) multi-fetal pregnancy; (3)
serious maternal medical illness (renal insufficiency,
congestive heart disease, etc.); (4) refusal to provide
written informed consent; and (5) a clinical emergency,
which prevented counseling of the patient about participating in the study, such as fetal distress or maternal
hemorrhage. All women provided written informed consent before collection of the samples. The use of clinical
data and collection and utilization of maternal and neonatal blood for research purposes was approved by the
Institutional Review Boards of the Sótero del Río Hospital, the Eunice Kennedy Shriver National Institute of
Child Health and Human Development, NIH, DHHS
and Virginia Commonwealth University. Ethnically, the
Chilean population is estimated at nearly 95% white and
mestizo (mixed white and Amerindian); 3% Amerindian;
and 2% other. Mixtures between the conquering Spaniards, largely Andalusians and Basques, and the
Mapuches (Araucanians) produced the principle Chilean
racial type (2002 census).
African American study design and population

A case-control study was initiated by searching clinical
databases and bank of biological samples at the University of Pennsylvania and the Perinatology Research
Branch (Eunice Kennedy Shriver National Institute of
Child Health and Human Development, NIH, DHHS),
at Wayne State University. Study subjects included
African American women and neonates in the following groups: 1) Cases - women with preeclampsia (n =
424) and neonates born to women with preeclampsia
(n = 375); and 2) Controls - women who delivered at
term with a normal pregnancy outcome (n = 412) and
neonates delivered at term to women with a normal
pregnancy outcome (n = 462). Participants in this
study received obstetrical care at the University of
Pennsylvania Medical Center, Philadelphia, PA or the
Hutzel Women’s Hospital, Detroit, MI. The criteria for
cases, controls, and exclusion of subjects in the African
American study were the same as described for the
Chilean study. Of the maternal and neonatal subjects
identified, 78% of samples were identified as maternalneonatal dyads. To obtain adequate sample sizes for
this study, therefore, maternal and neonatal samples
were tested independently and un-paired samples were
included in each group. The use of clinical data and
collection and utilization of maternal blood, cord
blood, and neonatal cheek swabs for research purposes
was approved by the Institutional Review Boards of the
University of Pennsylvania, Wayne State University, the
Eunice Kennedy Shriver National Institute of Child
Health and Human Development, NIH, DHHS, and
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Virginia Commonwealth University. African American
ethnicity was self-reported for all samples.
Clinical definitions

Preeclampsia was defined based on the presence of
gestational hypertension (systolic blood pressure ≥140
mmHg and/or diastolic blood pressure ≥90 mmHg)
and proteinuria (≥300 mg in a 24-hour urine collection, two or more dipstick measurement of 1+, or one
or more dipstick measurement ≥2+) according to
ACOG[1] and the National High Blood Pressure Education Program[30]. Patients were considered to have a
normal pregnancy outcome if they did not have any
medical, obstetrical, or surgical complication, and
delivered a term neonate (≥37 weeks) of appropriate
birth weight for gestational age[31,32] without
complications.
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Statistical Analysis

Logistic regression in R was used to test for differences
in clinical characteristics between disease classes for
non-genetic variables. Fisher’s exact tests implemented
in the PLINK software[34] were used to test individual
SNPs for genetic associations with case-control status
and to confirm Hardy-Weinberg equilibrium. SNPs with
an independent effect were further investigated by multiple logistic regression in R to condition by covariates
found to be significantly different between cases and
controls in the clinical characteristics analysis. An additive term for the significant SNP(s) was coded as 0, 1, or
2, based on copy number of the minor allele. Allele frequencies from the control groups were used to determine the odds ratios at which our study design had 80%
power at an alpha of 0.05. Power calculations were
made using the Genetic Power Calculator[35], assuming
a 5% disease prevalence.

Sample collection

Maternal blood samples were obtained from the mother
at the time of enrollment in the protocol. Umbilical
cord blood samples or neonate cheek swabs were
obtained immediately after delivery. Blood samples were
collected with a vacutainer into tubes containing EDTA.
The plasma tubes were balanced and centrifuged at
1300g for 10 minutes at 4°C to separate cellular components from clear plasma, and the samples were stored at
-70°C until assay.
DNA extraction

DNA was extracted from maternal and cord blood with
a Qiagen Autopure system using standard procedures
(Qiagen). DNA was extracted from neonate check swabs
using traditional methods as previously described[33].
Genotyping

Single-nucleotide polymorphism analysis was performed
using real-time allelic discrimination TaqMan assays
(Applied Biosystems) with modifications. All PCR reactions contained 25-75 ng of DNA, 6.25 ul TaqMan Universal Master Mix (Applied Biosystems) (2×), 0.3 ul
TaqMan Genotyping Assay (Applied Biosystems) (20×),
and water for a final volume of 12.5 ul. Real-time PCR
was performed on an ABI 7500 Fast Real-Time PCR
Machine (Applied Biosystems) under the following conditions: 50°C for 2 min, 95°C for 10 min, and 40 cycles of
amplification (92°C for 15 sec and 60°C for 1 min). For
each cycle, the software determined the fluorescent signal
from the VIC- or FAM- labeled probe (Applied Biosystems). Allelic discrimination for ERAP2 was performed
using TaqMan Genotyping assays C___3282749_20 for
SNP rs2549782 and C___25649505_10 for SNP
rs17408150 (Applied Biosystems).

Results
Clinical Characteristics of the Study Populations

Table 1 displays the demographic and clinical characteristics of mothers and neonates from pregnancies with
preeclampsia as well as controls. For Chilean subjects,
no significant differences were observed in maternal age
or fetal sex between groups. Consistent with previous
epidemiologic studies, Chilean patients with preeclampsia showed a significantly higher body mass index (BMI)
(P <0.001) and fewer previous live births (P = 0.007). In
accordance with preeclampsia resulting in intrauterine
growth restriction and indicated preterm birth, offspring
born to Chilean women with preeclampsia showed a significantly lower gestational age at delivery and birth
weight (P < 0.001). Similar results were observed in
African American subjects. Maternal age was not significantly different between cases and controls for either the
maternal or the fetal study groups, whereas, gestational
age at delivery and birth weight were significantly different between cases and controls for both groups (P <
0.001). Additionally, in the fetal group, mothers with
preeclampsia showed a significantly higher BMI (P =
0.049) and fewer previous live births (P = 0.040).
Although these measures were not significant in the
maternal study group, they were trending in the same
direction. In the fetal group, there were significantly
more female neonates than male (P = 0.024). Significant
differences in fetal sex have been reported in the literature, but results vary with some studies reporting a bias
towards male fetuses, some reporting a bias towards
female fetuses, and still others reporting no differences
in fetal sex in association with preeclampsia[36-44]. No
significant difference in fetal sex was observed between
cases and controls in the maternal study group.

Hill et al. BMC Medical Genetics 2011, 12:64
http://www.biomedcentral.com/1471-2350/12/64

Page 4 of 10

Table 1 Maternal and fetal characteristics of pregnancies diagnosed with preeclampsia and controls
Population
Chilean

Number of dyads

Maternal-Fetal Dyads

Maternal Age (years)

Controls

528

575

-

26.3 (7.5)

26.1 (6.2)

0.692
< 0.001

BMI (kg/m2)

26.4 (5.4)

24.5 (4.4)

Previous live births

0.80 (1.19)

0.99 (1.08)

0.007

Birthweight (grams)

2805.7 (815.7)

3423.2 (303.0)

< 0.001

Gestational age at delivery (weeks)
African American
Maternal

P-value

Preeclampsia

36.8 (3.4)

39.7 (1.1)

< 0.001

Fetal sex (% female)

45.8

53.3

0.492

Number of subjects
Maternal Age (years)

424
26.0 (6.3)

412
25.3 (5.9)

0.100

BMI (kg/m2)

30.9 (8.7)

29.7 (7.9)

0.070

Previous live births

3.2 (2.3)

3.3 (2.0)

0.529

Birthweight (grams)

2431.1 (893.8)

3292.1 (462.4)

< 0.001

36.0 (3.7)

39.5 (1.3)

< 0.001

52.4

48.4

0.253

Gestational age at delivery (weeks)
Fetal sex (% female)
African American

Number of subjects

375

462

-

Fetal

Maternal Age (years)
BMI (kg/m2)

25.8 (6.5)
31.0 (8.5)

25.8 (6.1)
29.8 (7.9)

0.947
0.049

Previous live births

3.1 (2.2)

3.4 (2.1)

0.040

Birthweight (grams)

2490.3 (851.8)

3294.7 (469.7)

< 0.001

36.2 (3.4)

39.5 (1.2)

< 0.001

54.8

47.0

0.024

Gestational age at delivery (weeks)
Fetal sex (% female)
Data are presented as means (SD). BMI, body mass index.

Chilean Population

The minor allele (G) frequencies for rs2549782 in
maternal and fetal samples were 0.3386 and 0.3292,
respectively. The minor “A” allele frequencies for
rs17408150 in maternal and fetal samples were 0.0422
and 0.0395 respectively. The minor allele frequencies
are consistent with published data and the Johnson et
al. study[21,45]. Single SNP analysis revealed no associations between ERAP2 polymorphisms rs2549782 and
rs17408150 and preeclampsia in either maternal or fetal
samples (Table 2). All SNPs were found to be in HardyWeinberg equilibrium in the maternal and fetal control
samples and no substantial linkage disequilibrium was
observed (R2 = 0.087 and 0.072, respectively).
African American Population

The minor allele (G) frequencies for rs2549782 in
maternal and fetal samples were 0.4103 and 0.3990
respectively. The minor allele frequencies are consistent
with published data and the Johnson et al. study[21,45].
We did not genotype rs17408150 in this population
because the minor “A” allele is reported to be < 1.0% in
individuals of African descent[45].
To establish the genetic similarity between the University of Pennsylvania Medical Center and Hutzel
Women’s Hospital African American samples, and
determine if these groups were appropriately combined
into a single study population, we compared allele

frequencies for three genes: ERAP2, MTHFR, and
COMT. Allele frequencies of both COMT and MTHFR
are not only known to differ among major ethnic categories, but substantial variation has also been demonstrated in subpopulations of each, including African
American[45-51]. Genotypes for MTHFR and COMT
were readily available for our samples and based on
their aforementioned ethnic variation, they represented
ideal genes for the genetic comparison of the two African American sample collection locations. Minor allele
frequencies for ERAP2, MTHFR, and COMT were comparable between both African American study sites
(Table 3). Additionally, the same COMT haplotype
structure was identified in each group and the haplotype
frequencies were comparable. The genetic similarity of
the two groups across six variable SNPs and COMT
haplotype structure and frequency, supported combing
the groups into a single African American study
population.
Single SNP analysis yielded a significant association
between the fetal rs2549782 and preeclampsia in the
African American population (P = 0.009), while no association was observed in the maternal SNP (Table 2).
Additional multiple logistic regression analysis was performed on the fetal group to adjust for risk factors of
preeclampsia (BMI, previous live births, and gravidity)
that were found to be significant in the clinical measures
analysis (Table 4). rs2549782 remained significant (P =
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Table 2 ERAP2 Allelic analysis for maternal and fetal samples with and without preeclampsia
Population
Chilean

ERAP2 SNP

Genotype (count)

Minor Allele

Frequency
Preeclampsia

Frequency
Controls

P-value

Odds Ratio
(95% C.I.)

GG (135)
TG (477)

G

0.330

0.347

0.393

0.925 (0.775, 1.104)

A

0.044

0.041

0.752

1.069 (0.706, 1.619)

G

0.333

0.326

0.751

1.033 (0.865, 1.234)

A

0.040

0.039

1.000

1.021 (0.665, 1.568)

G

0.429

0.391

0.133

1.166 (0.958, 1.420)

G

0.435

0.369

0.009

1.320 (1.075, 1.619)

Maternal
rs2549782

TT (491)
rs17408150

AA (2)
TA (89)
TT (1012)

Fetal
rs2549782

GG (124)
TG (477)
TT (500)

rs17408150

AA (0)
TA (87)
TT (1014)

African

Maternal

American

rs2549782

GG (147)
TG (383)
TT (295)

Fetal
rs2549782

GG (114)
TG (387)
TT (268)

SNP, single nucleotide polymorphism; C.I., confidence interval. The minor allele (G) of rs2549782 was found significantly more frequently in cases than controls in
African American fetal samples.

0.012) and was associated with an increased risk for
preeclampsia (OR = 1.529; CI: 1.099, 2.128). Of the
previously identified clinical measures tested, only the
number of previous live births remained significant,
with a larger number of previous live births decreasing
the risk for preeclampsia (OR = 0.845; CI: 0.744,
0.960). All SNPs were found to be in Hardy-Weinberg
equilibrium in the maternal and fetal groups. Finally,
we used two methods to confirm that the positive
association we observed was not attributed to population stratification based on the different African American sample collection locations. First, multiple logistic
regression analysis was performed in R to test whether
there was an interaction between the fetal genotype
and the sample collection location. No significant association was observed between a location × fetal
rs2549782 interaction and the risk for preeclampsia (P
= 0.098). Second, we performed a cluster analysis in
PLINK using a Cochran-Mantel-Haenszel model that
tested for overall disease/gene association, while controlling for clusters. After controlling for the sample
collection location, the fetal rs2549782 was still significantly associated with an increased risk for preeclampsia (P = 0.027; OR = 1.302; CI: 1.029, 1.648). These
results, in addition to the absence of evidence for differences in the rates of preeclampsia between African

American groups in the United States, justifies combining these samples in this study.

Discussion
Preeclampsia is one of the leading causes of maternal
and perinatal morbidity and mortality worldwide; yet its
etiology is poorly understood[1]. It is thought that poor
placentation and inadequate maternal blood supply lead
to placental hypoxia and the placental release of factors
that contribute to intravascular inflammation[52-54],
generalized endothelial dysfunction[55-59] and the
maternal symptoms. A genetic susceptibility to preeclampsia is well established and genes involved with the
immune system, inflammation, hemodynamics, endothelial dysfunction, oxidative stress, and angiogenesis have
been associated with preeclampsia[10,15-17]. The identification of genes involved in a variety of physiologic processes reflects the complex nature of this disorder.
It was recently reported by Johnson et al. that the
ERAP2 gene was associated with preeclampsia[21]. They
found an association with the rs2549782 SNP in an Australian/New Zealand maternal cohort and the
rs17408150 SNP in a Norwegian maternal cohort. In the
present study, we sought to test whether there were
associations between the two previously identified SNPs
in ERAP2 and risk for preeclampsia in two distinct

Hill et al. BMC Medical Genetics 2011, 12:64
http://www.biomedcentral.com/1471-2350/12/64

Page 6 of 10

Table 3 Genotype and Haplotype frequencies for ERAP2,
MTHFR, and COMT for African American samples
Group

Minor Allele Frequency

Table 4 Logistic regression model for preeclampsia,
including presence of the rs2549782 minor allele in
African American fetuses

Pennsylvania Michigan

Term

Estimate (S.E.) P-value Odds Ratio (95% C.I.)

Gene

SNP/
Haplotype

Minor
Allele

Fetal rs2549782

0.425 (0.169)

0.012

1.529 (1.099, 2.128)

Maternal ERAP2

rs2549782

G

0.397

0.374

Maternal BMI

0.021 (0.014)

0.140

1.021 (0.993, 1.049)

MTHFR

rs1801133

T

0.112

0.102

Previous live births

- 0.168 (0.065)

0.010

0.845 (0.744, 0.960)

COMT

rs6269
rs4633

G
T

0.393
0.292

0.384
0.316

Fetal Sex (% female)

0.355 (0.228)

0.120

1.426 (0.912, 2.231)

Intercept

-1.810 (0.492)

< 0.001

-

rs4818

G

0.200

0.215

rs4680

A

S.E., standard error; C.I., confidence interval; BMI, body mass index. The minor
allele (G) of rs2549782 significantly increases the risk for preeclampsia in
African American fetal samples; after correcting for risk factors identified to
modulate risk in this population.

0.276

0.291

ATCA

0.249

0.270

GCCA

0.027

0.021

GCGG

0.163

0.169

ACGG

0.037

0.048

ATCG
GCCG

0.043
0.203

0.045
0.194

ACCG
Fetal

0.278

0.253

ERAP2

rs2549782

G

0.359

0.424

MTHFR

rs1801133

T

0.120

0.133

COMT

rs6269

G

0.408

0.425

rs4633

T

0.319

0.300

rs4818

G

0.214

0.167

rs4680
ATCA

A

0.292
0.267

0.308
0.257

GCCA

0.022

0.051

GCGG

0.175

0.139

ACGG

0.040

0.028

ATCG

0.049

0.043

GCCG

0.207

0.235

ACCG

0.240

0.247

African American samples originated from two locations: the University of
Pennsylvania Medical Center, PA and Hutzel Women’s Hospital, MI. Minor
allele frequencies and haplotype frequencies were calculated from control
samples only at each location. When comparing locations, no test achieved a
significant difference at the 5% level using a Z-test for differences in two
independent proportions. SNP, single nucleotide polymorphism. COMT single
SNP frequencies are listed first, followed by COMT haplotypes formed by
those SNPs. COMT haplotype SNP order: rs6269, rs4633, rs4818, rs4680.

ethnic sample sets, Chilean and African American. In
contrast to the previous study, we also included fetal
samples to determine if the fetal ERAP2 gene was associated with risk for preeclampsia. We were motivated to
use this design by the fact that placental tissue is of fetal
origin and by interest in determining if any genetic association might be attributed to the sharing of alleles
between mother and fetus of one-half, in accordance
with Mendelian segregation patterns. We found that, in
African Americans, the presence of the minor allele (G)
of the rs2549782 SNP in the fetal ERAP2 gene increased
the risk for preeclampsia. We found no associations
between the two SNPs in the Chilean population, or the
rs2549782 SNP of the maternal ERAP2 gene in the African American population.

Preeclampsia is usually diagnosed after 20 weeks of
gestation, but it is thought that problems arising early in
pregnancy, especially during placentation, are the origin
of this disorder. ERAP2 is expressed in the syncytiotrophoblast and it has been reported that expression of this
gene was down-regulated in first trimester placentas of
women who subsequently developed preeclampsia
[23,29]. The identification of aberrant gene expression,
before maternal symptoms develop, suggests a role for
ERAP2 early in the disease course.
ERAP2 has the potential to contribute to the development of preeclampsia in multiple ways due to its involvement in the regulation of immune responses, proinflammatory cytokine production, and blood pressure
[22,25-28]. Preeclampsia is associated with a predominant T Helper Cell Type 1 (Th1) immune response,
which correlates to poor placentation, inflammation,
and endothelial dysfunction[60]. One of the primary
roles of ERAP2 is Human Leukocyte Antigen (HLA)
trimming of class 1-binding peptides. Decreased levels
of HLA-G have been reported in the circulation of
women with preeclampsia and reduced cell-surface
expression has been reported in trophoblasts
[22,27,61,62]. Interferon-gamma (IFN g) regulates both
ERAP2 and ERAP1 genes and they have been implicated
in immune activation and inflammation[28]. ERAP1,
which is closely related to and forms complexes with
ERAP2[61], also cleaves the cell surface receptors for
pro-inflammatory cytokines.
Pregnancy is a pro-inflammatory state, and inflammation is a key regulator of placentation[52,54,63,64].
Although normal pregnancy is pro-inflammatory, preeclampsia is associated with an exaggerated state of systemic inflammation, and aberrant production of
placental cytokines has been widely reported [65]. The
placental release of pro-inflammatory cytokines, or the
pre-existence of increased inflammation in the maternal
vasculature, could both contribute to the development
of preeclampsia. In addition to being pro-inflammatory,
many cytokines also regulate other processes that are
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important to the establishment and maintenance of
pregnancy. Placentation is tightly regulated by the oxygen balance to ensure adequate remodeling of the
maternal spiral arteries and sufficient perfusion of the
placenta[66]. Hypoxia Inducible Factor 1a (HIF-1a) is a
transcription factor that mediates cellular responses to
hypoxia and its expression is altered in preeclampsia
[67-69]. HIF-1a is regulated through oxygen dependent
and independent mechanisms, and several of the cytokines that are modulated by ERAP2 have been shown to
participate in the oxygen independent regulation
mechanisms[70].
Finally, ERAP2 regulates blood pressure through the
renin-angiotensin (RAS) pathway. Specifically, ERAP2
cleaves Angiotensin III and kallidin, both of which are
involved in regulating the dilation and constriction of
blood vessels[27]. Abnormalities in the processing of
these vasoactive substances could be a cause of maternal
high blood pressure, but they also might participate in
placental hypoxia, which is a key feature of preeclampsia. Defects in the RAS system have been demonstrated
both in the maternal system and fetal tissue[71,72],
further emphasizing the potential for ERAP2 to be
involved in the pathophysiology of preeclampsia.
Compared to white women (defined as not African
American, Asian, Hispanic, or Native American),
Caughey et al. found higher rates of preeclampsia
among African American women and lower rates
among Hispanic women [2]. Additionally, maternalpaternal ethnic discordance was reported to be associated with an increased incidence[2]. This supports the
hypothesis that the genetic basis for preeclampsia is heterogeneic. Our results, in conjunction with the findings
of Johnson et al., provide a potential explanation for the
observed differences between ethnic groups[21]. Four
ethnic populations were examined between the two studies. Allelic variation between European groups, especially Mediterranean, central Europe, and Scandinavia
are well characterized and support that they are distinct
populations[45-51]. The Chilean population is representative of a Mediterranean ethnic background, specifically
from Spanish decent. ERAP2 appears to contribute to
the risk for preeclampsia in three of the ethnic groups,
with two different allelic variants being associated with
risk. Maternal variants increase the risk for preeclampsia
in an Australian/New Zealand cohort and a Norwegian
cohort[21]. Although preeclampsia is thought to be a
placental disorder, the maternal phenotype and, in particular, the susceptibility of the maternal system to disease plays an important role in this disorder[18].
Chronic hypertension, obesity, diabetes, and renal disease, all put a woman at increased risk of developing
this disorder. A fetal variant increases the risk for preeclampsia in the African American cohort. Importantly,
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the placenta is fetal tissue and our results strengthen
the argument that primary defects in the placenta play a
central role in the development of preeclampsia. Moreover, this finding is consistent with the observation of
altered ERAP2 expression in placentas from women who
developed preeclampsia.
A strength of our study is the inclusion of both maternal and fetal genes, which gives us the ability to discriminate between maternal and fetal genetic effects. The
mother and fetus share fifty percent genetic identity so
failure to include both maternal and fetal genes in a
study creates the potential for a true association with
the unmeasured gene to manifest as an observed association with the measured gene based on the correlation
between maternal and fetal genotypes. There is also the
potential for both the maternal and fetal ERAP2 genes
to contribute to the risk for preeclampsia in a single
ethnic population. By measuring only the maternal
genes, an additional fetal association could be missed.
Thus, the question still remains whether both maternal
and fetal ERAP2 contribute to preeclampsia in different
ethnic populations where only maternal genes were
tested.
A second potential source of variation between ethnicities is the finding that two different SNPs in the
ERAP2 gene are associated with risk for preeclampsia.
Both of these SNPs are missense mutations that are predicted to alter the three-dimensional structure of the
protein and damage function. Additionally, rs2549782
resides within the highly conserved zinc-binding
domain. While both SNPs are expected reduce enzyme
function, they likely alter function to different degrees
and are not equivalent mutations. Moreover, the SNPs
reside in different domains of the protein and since
ERAP2 has multiple functions, the mutations could have
significantly different physiologic consequences.
Alternatively, the observed variation could be
explained by differences in linkage disequilibrium (LD)
structure between populations or failure to account for
larger haplotype structure. Although, the SNPs tested in
these studies are predicted to alter enzyme function,
they might not represent the causal variant in preeclampsia. These populations might share the same causal variant, but that variant could be in LD with
different SNPs in each population. Finally, two haplotypes of ERAP2 have recently been described that lead
to changes in mRNA decay and ultimately Major Histocompatibility Complex (MHC) class I presentation on
cell surfaces[73]. The haplotypes are composed of
numerous SNPs, with rs2549782 representing one of the
four coding SNPs that are considered diagnostic[73].
The frequency of each haplotype was estimated to be
0.5 across multiple ethnic groups and similar patterns of
long-range LD were also observed; indicating a single
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ancestral division of functional significance[73]. Neither
our study, nor Johnson et al. included the depth of
sequencing necessary to characterize the reported
haplotypes.
Our findings did not support a genetic association
between ERAP2 and the risk for preeclampsia in either
the Chilean population or the maternal African American
population. However, it should be noted that the present
study had limited statistical power to detect very small
effects. In the Chilean population, our study was adequately powered to detect Odds Ratios of at least 2.3 for
rs17408150 and 1.5-1.7 for rs2549782. In the African
American population, our study was adequately powered
to detect Odds Ratios of 1.6 - 1.9 for rs2549782. The
effect sizes for a single risk factor in a complex disorder
are expected to be relatively modest. Furthermore, we
only tested for associations between two SNPs in the
ERAP2 gene so we are unable to rule out the possibility
that different variants of this gene are associated with
risk for preeclampsia in these populations. Future studies,
increasing the number of markers to saturate the maternal and fetal ERAP2 genes, are needed to characterize the
haplotype structures of each group in order to distinguish
between maternal and fetal effects of this gene.

Conclusions
Our results show that fetal carriage of the minor allele
(G) of rs2549782 in the ERAP2 gene increases the risk
for preeclampsia in African Americans. We found no
associations between the maternal rs2549782 SNP of the
ERAP2 gene and risk for preeclampsia in either the African American or Chilean populations or the rs17408150
SNP of the ERAP2 gene and risk for preeclampsia in the
Chilean population. The association of rs2549782 with
risk for preeclampsia is consistent with findings of a
previous study that found an association of maternal
ERAP2 alleles in an Australian/New Zealand population
[21]. The results of our study, in combination with
those of Johnson et al.[21], describe replicated associations between ERAP2 and preeclampsia in three distinct
populations. These observations represent an important
step in understanding the pathophysiology of preeclampsia and how genetic variation might play a significant role in ethnic differences.
Acknowledgements and funding
This study was supported, in part, by P60MD002256 from the Eunice Kennedy
Shriver National Institute of Child Health and Human Development, NIH,
DHHS; R01HD034612 from the Eunice Kennedy Shriver National Institute of
Child Health and Human Development, NIH, DHHS; UL1RR031990 from the
National Center for Research Resources and the NIH Roadmap for Medical
Research, NIH; University of Pennsylvania Research foundation grant,
K12HD001265 (PI Driscoll; Scholar Srinivas) from the Eunice Kennedy Shriver
National Institute of Child Health and Human Development, NIH, DHHS; the
Intramural Research Program of the Eunice Kennedy Shriver National Institute

Page 8 of 10

of Child Health and Human Development, NIH, DHHS; and 1T32HLO9429001A1 from the National Heart, Lung, and Blood Institute, NIH, DHHS.
Author details
Department of Obstetrics and Gynecology and Center on Health Disparities,
Virginia Commonwealth University School of Medicine, Richmond, VA,
23298, United States. 2Department of Human and Molecular Genetics,
Virginia Commonwealth University School of Medicine, Richmond, VA,
23298, United States. 3Maternal and Child Health Research Program,
Department of Obstetrics & Gynecology, University of Pennsylvania School
of Medicine, Philadelphia, PA, 10104, United States. 4Perinatology Research
Branch, NICHD/NIH/DHHS, Bethesda and Detroit, MD and MI, 48201, United
States. 5Department of Obstetrics and Gynecology, Sótero del Río Hospital,
Santiago, Chile. 6Department of Obstetrics and Gynecology, Pontifica
Universidad Católica de Chile, Santiago, Chile.
1

Authors’ contributions
LDH participated in the design of the study, performed experiments,
performed the statistical analysis, and drafted the manuscript. DDH
performed experiments. TPY participated in the design of the study,
participated in the statistical analysis, and helped to draft the manuscript.
JPK provided Chilean and African American purified DNA for use in this
study and helped to draft the manuscript. RG coordinated sample collection
of Chilean subjects with JPK and RR and helped to draft the manuscript.
MAE provided African American DNA for use in this study and helped to
draft the manuscript. RR provided Chilean and African American DNA for
use in this study and helped to draft the manuscript. JFS conceived of the
study, participated in its design and coordinated and helped to draft the
manuscript. SS provided African American purified DNA for use in this study
and helped to draft the manuscript. All authors have read and approved the
final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 6 January 2011 Accepted: 11 May 2011
Published: 11 May 2011
References
1. ACOG practice bulletin. Diagnosis and management of preeclampsia
and eclampsia. Number 33, January 2002. American College of
Obstetricians and Gynecologists. Int J Gynaecol Obstet 2002, 77(1):67-75.
2. Caughey AB, Stotland NE, Washington AE, Escobar GJ: Maternal ethnicity,
paternal ethnicity, and parental ethnic discordance: predictors of
preeclampsia. Obstet Gynecol 2005, 106(1):156-161.
3. Zhou Y, Damsky CH, Chiu K, Roberts JM, Fisher SJ: Preeclampsia is
associated with abnormal expression of adhesion molecules by invasive
cytotrophoblasts. J Clin Invest 1993, 91(3):950-960.
4. Kadyrov M, Schmitz C, Black S, Kaufmann P, Huppertz B: Pre-eclampsia and
maternal anaemia display reduced apoptosis and opposite invasive
phenotypes of extravillous trophoblast. Placenta 2003, 24(5):540-548.
5. Kadyrov M, Kingdom JC, Huppertz B: Divergent trophoblast invasion and
apoptosis in placental bed spiral arteries from pregnancies complicated
by maternal anemia and early-onset preeclampsia/intrauterine growth
restriction. Am J Obstet Gynecol 2006, 194(2):557-563.
6. Brosens I: A Study of the Spiral Arteries of the Decidua Basalis in
Normotensive and Hypertensive Pregnancies. J Obstet Gynaecol Br
Commonw 1964, 71:222-230.
7. Brosens I, Robertson WB, Dixon HG: The physiological response of the
vessels of the placental bed to normal pregnancy. J Pathol Bacteriol 1967,
93(2):569-579.
8. Brosens I: The uteroplacental vessels at term: the distribution and extent
of physiological changes. Trophoblast Res 1988, 3:61-68.
9. Ilekis JV, Reddy UM, Roberts JM: Preeclampsia–a pressing problem: an
executive summary of a National Institute of Child Health and Human
Development workshop. Reprod Sci 2007, 14(6):508-523.
10. Chesley LC, Annitto JE, Cosgrove RA: The familial factor in toxemia of
pregnancy. Obstet Gynecol 1968, 32(3):303-311.
11. Lie RT, Rasmussen S, Brunborg H, Gjessing HK, Lie-Nielsen E, Irgens LM:
Fetal and maternal contributions to risk of pre-eclampsia: population
based study. Bmj 1998, 316(7141):1343-1347.

Hill et al. BMC Medical Genetics 2011, 12:64
http://www.biomedcentral.com/1471-2350/12/64

12. Esplin MS, Fausett MB, Fraser A, Kerber R, Mineau G, Carrillo J, Varner MW:
Paternal and maternal components of the predisposition to
preeclampsia. N Engl J Med 2001, 344(12):867-872.
13. Cnattingius S, Reilly M, Pawitan Y, Lichtenstein P: Maternal and fetal
genetic factors account for most of familial aggregation of
preeclampsia: a population-based Swedish cohort study. Am J Med Genet
A 2004, 130A(4):365-371.
14. Skjaerven R, Vatten LJ, Wilcox AJ, Ronning T, Irgens LM, Lie RT: Recurrence
of pre-eclampsia across generations: exploring fetal and maternal
genetic components in a population based cohort. Bmj 2005,
331(7521):877.
15. Chappell S, Morgan L: Searching for genetic clues to the causes of preeclampsia. Clin Sci (Lond) 2006, 110(4):443-458.
16. Goddard KA, Tromp G, Romero R, Olson JM, Lu Q, Xu Z, Parimi N, Nien JK,
Gomez R, Behnke E, et al: Candidate-gene association study of mothers
with pre-eclampsia, and their infants, analyzing 775 SNPs in 190 genes.
Hum Hered 2007, 63(1):1-16.
17. Parimi N, Tromp G, Kuivaniemi H, Nien JK, Gomez R, Romero R,
Goddard KA: Analytical approaches to detect maternal/fetal genotype
incompatibilities that increase risk of pre-eclampsia. BMC Med Genet
2008, 9:60.
18. Ness RB, Roberts JM: Heterogeneous causes constituting the single
syndrome of preeclampsia: a hypothesis and its implications. Am J
Obstet Gynecol 1996, 175(5):1365-1370.
19. Di Renzo GC: The great obstetrical syndromes. J Matern Fetal Neonatal
Med 2009, 22(8):633-635.
20. Romero R: Prenatal medicine: the child is the father of the man. 1996. J
Matern Fetal Neonatal Med 2009, 22(8):636-639.
21. Johnson MP, Roten LT, Dyer TD, East CE, Forsmo S, Blangero J,
Brennecke SP, Austgulen R, Moses EK: The ERAP2 gene is associated with
preeclampsia in Australian and Norwegian populations. Hum Genet 2009,
126(5):655-666.
22. Tsujimoto M, Hattori A: The oxytocinase subfamily of M1
aminopeptidases. Biochim Biophys Acta 2005, 1751(1):9-18.
23. Fruci D, Giacomini P, Nicotra MR, Forloni M, Fraioli R, Saveanu L, van
Endert P, Natali PG: Altered expression of endoplasmic reticulum
aminopeptidases ERAP1 and ERAP2 in transformed non-lymphoid
human tissues. J Cell Physiol 2008, 216(3):742-749.
24. Zhang Y, Cui Y, Zhou Z, Sha J, Li Y, Liu J: Altered global gene expressions
of human placentae subjected to assisted reproductive technology
treatments. Placenta 31(4):251-258.
25. Taylor A: Aminopeptidases: structure and function. Faseb J 1993,
7(2):290-298.
26. Hattori A, Matsumoto H, Mizutani S, Tsujimoto M: Molecular cloning of
adipocyte-derived leucine aminopeptidase highly related to placental
leucine aminopeptidase/oxytocinase. J Biochem 1999, 125(5):931-938.
27. Tanioka T, Hattori A, Masuda S, Nomura Y, Nakayama H, Mizutani S,
Tsujimoto M: Human leukocyte-derived arginine aminopeptidase. The
third member of the oxytocinase subfamily of aminopeptidases. J Biol
Chem 2003, 278(34):32275-32283.
28. Tanioka T, Hattori A, Mizutani S, Tsujimoto M: Regulation of the human
leukocyte-derived arginine aminopeptidase/endoplasmic reticulumaminopeptidase 2 gene by interferon-gamma. Febs J 2005,
272(4):916-928.
29. Founds SA, Conley YP, Lyons-Weiler JF, Jeyabalan A, Hogge WA, Conrad KP:
Altered global gene expression in first trimester placentas of women
destined to develop preeclampsia. Placenta 2009, 30(1):15-24.
30. Report of the National High Blood Pressure Education Program Working
Group on High Blood Pressure in Pregnancy. Am J Obstet Gynecol 2000,
183(1):S1-S22.
31. Alexander GR, Kogan M, Martin J, Papiernik E: What are the fetal growth
patterns of singletons, twins, and triplets in the United States? Clin
Obstet Gynecol 1998, 41(1):114-125.
32. Gonzalez RP, Gomez RM, Castro RS, Nien JK, Merino PO, Etchegaray AB,
Carstens MR, Medina LH, Viviani PG, Rojas IT: [A national birth weight
distribution curve according to gestational age in Chile from 1993 to
2000]. Rev Med Chil 2004, 132(10):1155-1165.
33. Wang H, Parry S, Macones G, Sammel MD, Ferrand PE, Kuivaniemi H,
Tromp G, Halder I, Shriver MD, Romero R, et al: Functionally significant
SNP MMP8 promoter haplotypes and preterm premature rupture of
membranes (PPROM). Hum Mol Genet 2004, 13(21):2659-2669.

Page 9 of 10

34. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, Maller J,
Sklar P, de Bakker PI, Daly MJ, et al: PLINK: a tool set for whole-genome
association and population-based linkage analyses. Am J Hum Genet
2007, 81(3):559-575.
35. Purcell S, Cherny SS, Sham PC: Genetic Power Calculator: design of
linkage and association genetic mapping studies of complex traits.
Bioinformatics 2003, 19(1):149-150.
36. Toivanen P, Hirvonen T: Sex ratio of newborns: preponderance of males
in toxemia of pregnancy. Science 1970, 170(954):187-188.
37. Juberg RC, Gaar DG, Humphries JR, Cenac PL, Zambie MF: Sex ratio in the
progeny of mothers with toxemia of pregnancy. J Reprod Med 1976,
16(6):299-302.
38. Campbell DM, MacGillivray I, Carr-Hill R, Samphier M: Fetal sex and preeclampsia in primigravidae. Br J Obstet Gynaecol 1983, 90(1):26-27.
39. Arngrimsson R, Walker JJ, Geirsson RT, Bjornsson S: A low male/female sex
ratio in offspring of women with a family history of pre-eclampsia and
eclampsia. Br J Obstet Gynaecol 1993, 100(5):496-497.
40. Sanchez AR, Macho JE, Estrada HV, Gonzalez AL: [Does the gender of the
fetus determine the severity of preeclampsia-eclampsia?]. Ginecol Obstet
Mex 1996, 64:18-20.
41. Khong TY, Staples A, Chan AS, Keane RJ, Wilkinson CS: Pregnancies
complicated by retained placenta: sex ratio and relation to preeclampsia. Placenta 1998, 19(8):577-580.
42. Makhseed M, Musini VM, Ahmed MA: Association of fetal gender with
pregnancy-induced hypertension and pre-eclampsia. Int J Gynaecol
Obstet 1998, 63(1):55-56.
43. Basso O, Olsen J: Sex ratio and twinning in women with hyperemesis or
pre-eclampsia. Epidemiology 2001, 12(6):747-749.
44. Jongbloet PH: Offspring sex ratio at population level versus early and
late onset preeclampsia. Early Hum Dev 2004, 79(2):159-163.
45. Sherry ST, Ward MH, Kholodov M, Baker J, Phan L, Smigielski EM, Sirotkin K:
dbSNP: the NCBI database of genetic variation. Nucleic Acids Res 2001,
29(1):308-311.
46. Stevenson RE, Schwartz CE, Du YZ, Adams MJ Jr: Differences in
methylenetetrahydrofolate reductase genotype frequencies, between
Whites and Blacks. Am J Hum Genet 1997, 60(1):229-230.
47. van der Put NM, Eskes TK, Blom HJ: Is the common 677C–>T mutation in
the methylenetetrahydrofolate reductase gene a risk factor for neural
tube defects? A meta-analysis. Qjm 1997, 90(2):111-115.
48. Schneider JA, Rees DC, Liu YT, Clegg JB: Worldwide distribution of a
common methylenetetrahydrofolate reductase mutation. Am J Hum
Genet 1998, 62(5):1258-1260.
49. Palmatier MA, Kang AM, Kidd KK: Global variation in the frequencies of
functionally different catechol-O-methyltransferase alleles. Biol Psychiatry
1999, 46(4):557-567.
50. Schwahn B, Rozen R: Polymorphisms in the methylenetetrahydrofolate
reductase gene: clinical consequences. Am J Pharmacogenomics 2001,
1(3):189-201.
51. Domschke K, Deckert J, O’Donovan M C, Glatt SJ: Meta-analysis of COMT
val158met in panic disorder: ethnic heterogeneity and gender
specificity. Am J Med Genet B Neuropsychiatr Genet 2007, 144B(5):667-673.
52. Redman CW, Sargent IL: Pre-eclampsia, the placenta and the maternal
systemic inflammatory response–a review. Placenta 2003, 24(Suppl A):
S21-27.
53. Gervasi MT, Chaiworapongsa T, Pacora P, Naccasha N, Yoon BH,
Maymon E, Romero R: Phenotypic and metabolic characteristics of
monocytes and granulocytes in preeclampsia. Am J Obstet Gynecol
2001, 185(4):792-797.
54. Redman CW, Sargent IL: Placental stress and pre-eclampsia: a revised
view. Placenta 2009, 30(Suppl A):S38-42.
55. Roberts JM, Taylor RN, Musci TJ, Rodgers GM, Hubel CA, McLaughlin MK:
Preeclampsia: an endothelial cell disorder. Am J Obstet Gynecol 1989,
161(5):1200-1204.
56. Roberts JM, Taylor RN, Goldfien A: Clinical and biochemical evidence of
endothelial cell dysfunction in the pregnancy syndrome preeclampsia.
Am J Hypertens 1991, 4(8):700-708.
57. Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, Libermann TA,
Morgan JP, Sellke FW, Stillman IE, et al: Excess placental soluble fms-like
tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction,
hypertension, and proteinuria in preeclampsia. J Clin Invest 2003,
111(5):649-658.

Hill et al. BMC Medical Genetics 2011, 12:64
http://www.biomedcentral.com/1471-2350/12/64

Page 10 of 10

58. Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, Schisterman EF,
Thadhani R, Sachs BP, Epstein FH, et al: Circulating angiogenic factors and
the risk of preeclampsia. N Engl J Med 2004, 350(7):672-683.
59. Powers RW, Catov JM, Bodnar LM, Gallaher MJ, Lain KY, Roberts JM:
Evidence of endothelial dysfunction in preeclampsia and risk of adverse
pregnancy outcome. Reprod Sci 2008, 15(4):374-381.
60. Saito S, Sakai M: Th1/Th2 balance in preeclampsia. J Reprod Immunol 2003,
59(2):161-173.
61. Saveanu L, Carroll O, Lindo V, Del Val M, Lopez D, Lepelletier Y, Greer F,
Schomburg L, Fruci D, Niedermann G, et al: Concerted peptide trimming
by human ERAP1 and ERAP2 aminopeptidase complexes in the
endoplasmic reticulum. Nat Immunol 2005, 6(7):689-697.
62. Sargent IL, Borzychowski AM, Redman CW: Immunoregulation in normal
pregnancy and pre-eclampsia: an overview. Reprod Biomed Online 2006,
13(5):680-686.
63. Borzychowski AM, Sargent IL, Redman CW: Inflammation and preeclampsia. Semin Fetal Neonatal Med 2006, 11(5):309-316.
64. Moffett A, Hiby SE: How Does the maternal immune system contribute to
the development of pre-eclampsia? Placenta 2007, 28(Suppl A):S51-56.
65. Rusterholz C, Hahn S, Holzgreve W: Role of placentally produced
inflammatory and regulatory cytokines in pregnancy and the etiology of
preeclampsia. Semin Immunopathol 2007, 29(2):151-162.
66. Caniggia I, Winter JL: Adriana and Luisa Castellucci Award lecture 2001.
Hypoxia inducible factor-1: oxygen regulation of trophoblast
differentiation in normal and pre-eclamptic pregnancies–a review.
Placenta 2002, 23(Suppl A):S47-57.
67. Semenza GL: Hypoxia-inducible factor 1: master regulator of O2
homeostasis. Curr Opin Genet Dev 1998, 8(5):588-594.
68. Becker CM, Rohwer N, Funakoshi T, Cramer T, Bernhardt W, Birsner A,
Folkman J, D’Amato RJ: 2-methoxyestradiol inhibits hypoxia-inducible
factor-1{alpha} and suppresses growth of lesions in a mouse model of
endometriosis. Am J Pathol 2008, 172(2):534-544.
69. Kanasaki K, Kalluri R: The biology of preeclampsia. Kidney Int 2009,
76(8):831-837.
70. Patel J, Landers K, Mortimer RH, Richard K: Regulation of Hypoxia
Inducible Factors (HIF) in Hypoxia and Normoxia During Placental
Development. Placenta 31(11):951-957.
71. Irani RA, Xia Y: The functional role of the renin-angiotensin system in
pregnancy and preeclampsia. Placenta 2008, 29(9):763-771.
72. Vefring HK, Wee L, Jugessur A, Gjessing HK, Nilsen ST, Lie RT: Maternal
angiotensinogen (AGT) haplotypes, fetal renin (REN) haplotypes and risk
of preeclampsia; estimation of gene-gene interaction from family-triad
data. BMC Med Genet 11:90.
73. Andres AM, Dennis MY, Kretzschmar WW, Cannons JL, Lee-Lin SQ, Hurle B,
Schwartzberg PL, Williamson SH, Bustamante CD, Nielsen R, et al: Balancing
selection maintains a form of ERAP2 that undergoes nonsense-mediated
decay and affects antigen presentation. PLoS Genet 6(10):e1001157.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2350/12/64/prepub
doi:10.1186/1471-2350-12-64
Cite this article as: Hill et al.: Fetal ERAP2 variation is associated with
preeclampsia in African Americans in a case-control study. BMC Medical
Genetics 2011 12:64.

Submit your next manuscript to BioMed Central
and take full advantage of:
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at
www.biomedcentral.com/submit

